J&J tops list in commercializing drugs; Perrigo to sell copycat of AndroGel;

@FiercePharma: GSK to hack jobs in Europe where austerity has taken toll. Report | Follow @FiercePharma

@EricPFierce: With sale of Tysabri rights to Biogen Idec, Elan is now flush with cash and looking for something to buy. News | Follow @EricPFierce

@AlisonBFierce: Merck and GlaxoSmithKline will work with the GAVI Alliance to provide low-cost HPV vaccines to developing countries. Article | Follow @AlisonBFierce

> Danish drugmaker Lundbeck, which earlier had warned that earnings would be restrained, today said higher costs cut deeply into its bottom line. Story

> A court has said that Forest Laboratories ($FRX) has pushed back an effort to create a class action out of litigation that claims the company was not forthright in its marketing of antidepressants Celexa and Lexapro to patients under the age of 18. News

> Perrigo ($PRGO) says it has gotten FDA approval to make an equivalent version of AbbVie's ($ABBV) testosterone med, AndroGel. Release

> Elite Pharmaceuticals says the FDA has given it approval to begin manufacturing a generic of Duramed's Revia opioid painkiller. Item

> A new report from IDEA Pharma says Johnson & Johnson ($JNJ) has had the most success getting drugs to market and then money to shareholders. Report

Medical Device News

 @FierceMedDev: Exosome draws $5M in financing for molecular Dx work. Item | Follow @FierceMedDev

 @MarkHFierce: House Majority Leader Eric Cantor has revived the device tax repeal push, as part of Republicans' new platform. Story | Follow @MarkHFierce

 @DamianFierce: Allergan is looking to sell off its Lap-Band business as revenues continue to plummet. News | Follow @DamianFierce

> HeartMate sales propel Thoratec's Q4 revenue jump. Article

> Zoll gains Japan's sign-off for intravascular temperature management device. Report

Biotech News

 @FierceBiotech: Pfizer partner Protalix soars on sale speculation. Report | Follow @FierceBiotech

@JohnCFierce: So Elan has $3.25B to play with? Will they blow it? Analysis | Follow @JohnCFierce

@RyanMFierce: No surprise here. HISUN doesn't want exclusive license to Celsion's ThermoDox for the China market. Release | Follow @RyanMFierce

> Catabasis raises $9M for PhII-ready drug development program. News

> Ipsen, insolvent biotech partner find buyer for troubled hemophilia drug. Report

Drug Delivery News

> Cloaked nanoparticles look like blood cells, carry drugs. Story

> FDA to review BTG's varicose vein foam injection. News

> Rockwell shows iron delivery drug for dialysis improves treatment. Article

> Langer's Kala scores Cystic Fibrosis Foundation grant. Report

Biomarkers News

> Brain biomarker may help open door to personalized depression drugs. Report

> FDA will make use of GVK biomarker database. Item

> Biomarker could be key to MS Dx and targeted treatment. Article

> Molecules that could predict cancer growth detected. News

> Researcher names protein as plausible autism biomarker. Story

And Finally... A study of medical students who attended schools with strict bans on taking gifts hit the streets being less likely to be influenced by drugmakers. More